The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant pyrotinib and inetetamab in combination with chemotherapy for locally advanced HER2-positive breast cancer (NeoPICD study): A prospective, multicenter, open-label, single-arm study.
 
Yiying Xu
No Relationships to Disclose
 
Xue Wu
No Relationships to Disclose
 
Chenghui Yang
No Relationships to Disclose
 
Erjie Xia
No Relationships to Disclose
 
Yinghao Wang
No Relationships to Disclose
 
Xuanxuan Dai
No Relationships to Disclose
 
Haiguang Liu
No Relationships to Disclose
 
Yizuo Chen
No Relationships to Disclose
 
Wenqian Wang
No Relationships to Disclose
 
Guilong Guo
No Relationships to Disclose
 
Weili Wu
No Relationships to Disclose
 
Xiaoyang Li
No Relationships to Disclose
 
Ouchen Wang
No Relationships to Disclose